Directorio

If you join this study, you will be randomly placed into one of two groups. One group will get the study medicine called efgartigimod, and the other group will get a placebo, which is a fake medicine. Both are given through a tube in your vein, called an IV. You will get the medicine or placebo for the first 4 weeks. After that, depending on your platelet count, you will keep getting it every week or every other week for 20 more weeks. After 24 weeks, you may be able to join the next part of the study, where everyone gets the real medicine for up to 52 weeks. If the medicine does not work well enough after 12 weeks, you might be able to switch to the real medicine earlier.

We are doing this study to determine the safety and effectiveness of an experimental medical device called the GORE Ascending Stent Graft (ASG Device) for the treatment of aortic diseases.

We are doing this study to find out if a study drug called sacituzumab govitecan can improve outcomes for patients with high risk, early triple negative breast cancer (TNBC). We want to know if giving this drug in combination with pembrolizumab will work better than pembrolizumab on its own or better than pembrolizumab + capecitabine.

This study begins with about one month of screening tests, such as blood tests and exams, to see if a person can join. If eligible, people will be placed into one of two groups by chance. One group will receive a medicine called lisaftoclax with another medicine called azacitidine. The other group will receive a placebo, which has no active medicine, along with azacitidine. Treatment happens in cycles that last 28 days. During each cycle, lisaftoclax or placebo is taken by mouth for 14 days, and azacitidine is given by a shot or through a vein for 7 days. At the start, there will be more clinic visits, and visits may become less frequent over time. Participants will continue treatment as long as it is helping and side effects are manageable. After stopping treatment, there will be a follow up visit to check safety.

We are doing this study to find out if an experimental drug called asciminib (the study drug) is a safe and effective option for people with metastatic HER2+ breast cancer with brain metastases when it is combined with trastuzumab.